Advertisement

Verbal Memory

  • Tomiki Sumiyoshi
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 228)

Abstract

Verbal memory is impaired in neurological and psychiatric conditions and provides one of the main targets of intervention. Specifically, this cognitive domain has been shown to provide a major determinant of outcome in schizophrenia and mood disorders. Therefore, verbal memory disturbances should be focused in the development of novel pharmacological and psychosocial therapeutics. Effective integration between preclinical and clinical studies should provide a key to the pursuit of drugs enhancing verbal memory.

Keywords

Verbal memory Learning memory Psychiatry Antipsychotic drugs Cognitive enhancers Functional outcome 

Notes

Acknowledgment

This work was supported by grants-in-aid for Scientific Research from Japan Society for the Promotion of Science (No. 26461761), Health and Labour Sciences Research Grants for Comprehensive Research on Disability, Health, and Welfare (H24-Seishin-Ippan-002 and H26-Seishin-Ippan-011), and Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP.

The author thanks Drs. Herbert Y. Meltzer, Philip D. Harvey, Richard Keefe, and Sohee Park for the discussions.

References

  1. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, Clark L, Cubukcuoglu Z, Dias VV, Dittmann S, Ferrier IN, Fleck DE, Frangou S, Gallagher P, Jones L, Kieseppa T, Martinez-Aran A, Melle I, Moore PB, Mur M, Pfennig A, Raust A, Senturk V, Simonsen C, Smith DJ, Bio DS, Soeiro-de-Souza MG, Stoddart SD, Sundet K, Szoke A, Thompson JM, Torrent C, Zalla T, Craddock N, Andreassen OA, Leboyer M, Vieta E, Bauer M, Worhunsky PD, Tzagarakis C, Rogers RD, Geddes JR, Goodwin GM (2013) Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 128:149–162CrossRefPubMedGoogle Scholar
  2. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82–89CrossRefPubMedGoogle Scholar
  3. Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK (2011) The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology 36:1587–1592CrossRefPubMedCentralPubMedGoogle Scholar
  4. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675–682CrossRefPubMedGoogle Scholar
  5. Depp CA, Mausbach BT, Harmell AL, Savla GN, Bowie CR, Harvey PD, Patterson TL (2012) Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord 14:217–226CrossRefPubMedCentralPubMedGoogle Scholar
  6. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64:1115–1122CrossRefPubMedGoogle Scholar
  7. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26:119–136CrossRefPubMedGoogle Scholar
  8. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18:448–454CrossRefPubMedGoogle Scholar
  9. Harvey PD (2009) Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 19:324–335CrossRefPubMedGoogle Scholar
  10. Harvey PD, Raykov T, Twamley EW, Vella L, Heaton RK, Patterson TL (2011) Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry 168:1195–1201CrossRefPubMedCentralPubMedGoogle Scholar
  11. Hellvin T, Sundet K, Simonsen C, Aminoff SR, Lagerberg TV, Andreassen OA, Melle I (2012) Neurocognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disord 14:227–238CrossRefPubMedGoogle Scholar
  12. Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M (2008) Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr Res 101:320–330CrossRefPubMedGoogle Scholar
  13. Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Sweeney JA (2013) Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. Am J Psychiatry 170:1275–1284CrossRefPubMedGoogle Scholar
  14. Horiguchi M, Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition deficits in rats. Psychopharmacology (Berl) 221:205–215CrossRefGoogle Scholar
  15. Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 37:2175–2183CrossRefPubMedCentralPubMedGoogle Scholar
  16. Keefe RS, Fenton WS (2007) How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 33:912–920CrossRefPubMedCentralPubMedGoogle Scholar
  17. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004) The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68:283–297CrossRefPubMedGoogle Scholar
  18. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647CrossRefPubMedGoogle Scholar
  19. Leifker FR, Patterson TL, Heaton RK, Harvey PD (2011) Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull 37:334–343CrossRefPubMedCentralPubMedGoogle Scholar
  20. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165–178CrossRefPubMedGoogle Scholar
  21. Matsumoto J, Uehara T, Urakawa S, Takamura Y, Sumiyoshi T, Suzuki M, Ono T, Nishijo H (2014) 3D video analysis of the novel object recognition test in rats. Behav Brain Res 272:16–24CrossRefPubMedGoogle Scholar
  22. Meltzer HY, Sumiyoshi T (2003) Atypical antipsychotic drugs improve cognition in schizophrenia. Biol Psychiatry 53:265–267, author reply 267–268CrossRefPubMedGoogle Scholar
  23. Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213:289–305CrossRefGoogle Scholar
  24. Michalopoulou PG, Lewis SW, Wykes T, Jaeger J, Kapur S (2013) Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. Eur Neuropsychopharmacol 23:790–798CrossRefPubMedGoogle Scholar
  25. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315–328CrossRefGoogle Scholar
  26. Nuechterlein KH, Green MF (2006) MATRICS consensus cognitive battery. MATRICS Assessment, Los Angeles, CAGoogle Scholar
  27. Parkin AJ (1999) Memory: a guide for professionals. Wiley, West SussexGoogle Scholar
  28. Sumiyoshi T (2015) Cognitive impairment in schizophrenia. In: Stolerman I, Price LH (eds) Encyclopedia of Psychopharmacology, 2nd edn. Springer, New YorkGoogle Scholar
  29. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia [letter]. J Clin Psychopharmacol 20:386–388CrossRefPubMedGoogle Scholar
  30. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722–1725CrossRefPubMedGoogle Scholar
  31. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861–868CrossRefPubMedGoogle Scholar
  32. Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY (2006a) Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int J Neuropsychopharmacol 9:677–683CrossRefPubMedGoogle Scholar
  33. Sumiyoshi T, Higuchi Y, Kawasaki Y, Matsui M, Kato K, Yuuki H, Arai H, Kurachi M (2006b) Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300. Prog Neuropsychopharmacol Biol Psychiatry 30:1299–1303CrossRefPubMedGoogle Scholar
  34. Sumiyoshi T, Higuchi Y, Itoh T, Matsui M, Arai H, Suzuki M, Kurachi M, Sumiyoshi C, Kawasaki Y (2009) Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta. Psychiatry Res 172:180–183CrossRefPubMedGoogle Scholar
  35. Sumiyoshi T, Higuchi Y, Itoh T, Kawasaki Y (2011) Electrophysiological imaging evaluation of schizophrenia and treatment response. In: Risner MS (ed) Handbook of schizophrenia spectrum disorders, vol 3. Springer, New YorkGoogle Scholar
  36. Sumiyoshi T, Higuchi Y, Uehara T (2013) Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci 7:140PubMedCentralPubMedGoogle Scholar
  37. Torres IJ, DeFreitas CM, DeFreitas VG, Bond DJ, Kunz M, Honer WG, Lam RW, Yatham LN (2011) Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 41:971–982CrossRefPubMedGoogle Scholar
  38. Tulving EC, Fergus IM (2000) The Oxford handbook of memory. Oxford University Press, OxfordGoogle Scholar
  39. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457–472CrossRefPubMedGoogle Scholar
  40. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211–224CrossRefPubMedGoogle Scholar
  41. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martinez-Aran A, Dittmann S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KN (2010) The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord 12:351–363CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Clinical Research PromotionNational Center of Neurology and PsychiatryTokyoJapan

Personalised recommendations